Sotabase

Career

· Engineering, Applied Intuition2024–

Publications (62)

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
New England Journal of Medicine · 2014
1,811
cited
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
New England Journal of Medicine · 2014
1,360
cited
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
New England Journal of Medicine · 2015
530
cited
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Pharmacotherapy · 2010
435
cited
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
Hepatology · 2015
292
cited
Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
Hepatology · 2015
207
cited
O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
2015
149
cited
Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
Hepatology · 2015
144
cited
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
Nature reviews: Gastroenterology & hepatology · 2022
132
cited
Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model
Antimicrobial Agents and Chemotherapy · 2010
131
cited
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Gastroenterology · 2017
103
cited
Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy · 2008
93
cited
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
Hepatology · 2015
83
cited
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
Clinical Infectious Diseases · 2016
75
cited
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
Clinical Infectious Diseases · 2016
70
cited
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Gastroenterology · 2016
60
cited
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Gastroenterology · 2016
55
cited
In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.
Journal of Antimicrobial Chemotherapy · 2008
47
cited
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
Journal of Hepatology · 2022
43
cited
The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment
Hepatology Communications · 2017
36
cited
Sotabase
Jenny Yang | Researcher Profile | Sotabase | Sotabase